ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 891,68
-0,19%
Dow Jones
44 873,28
0,71%
DAX
21 585,93
0,35%
Brent Oil
74,585
0,01%
Bitcoin
97 482,73
0,89%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Keros Therapeutics Inc (KROS)

  7. Keros Therapeutics Inc (KROS) Actualités

KROS

Keros Therapeutics (KROS)

Keros Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KROS
DateHeureSourceTitreSymboleSociété
30/01/202514h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
30/01/202514h00GlobeNewswire Inc.Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech ConferenceNASDAQ:KROSKeros Therapeutics Inc
24/01/202522h15Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:KROSKeros Therapeutics Inc
21/01/202514h00GlobeNewswire Inc.Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance ElriterceptNASDAQ:KROSKeros Therapeutics Inc
15/01/202512h30GlobeNewswire Inc.Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS TrialNASDAQ:KROSKeros Therapeutics Inc
12/12/202412h00GlobeNewswire Inc.Keros Therapeutics Announces Update on the Phase 2 TROPOS TrialNASDAQ:KROSKeros Therapeutics Inc
10/12/202401h30GlobeNewswire Inc.Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and ExpositionNASDAQ:KROSKeros Therapeutics Inc
03/12/202413h00GlobeNewswire Inc.Keros Therapeutics Announces Global License Agreement with Takeda to Advance ElriterceptNASDAQ:KROSKeros Therapeutics Inc
26/11/202414h00GlobeNewswire Inc.Keros Therapeutics Announces Participation at Upcoming Healthcare ConferencesNASDAQ:KROSKeros Therapeutics Inc
12/11/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
08/11/202422h18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
06/11/202422h22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KROSKeros Therapeutics Inc
06/11/202414h00GlobeNewswire Inc.Keros Therapeutics to Present at the Guggenheim Healthcare Innovation ConferenceNASDAQ:KROSKeros Therapeutics Inc
05/11/202415h00GlobeNewswire Inc.Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and ExpositionNASDAQ:KROSKeros Therapeutics Inc
16/10/202414h00GlobeNewswire Inc.Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical OfficerNASDAQ:KROSKeros Therapeutics Inc
12/09/202414h00GlobeNewswire Inc.Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
03/09/202414h00GlobeNewswire Inc.Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS TrialNASDAQ:KROSKeros Therapeutics Inc
07/08/202422h01GlobeNewswire Inc.Keros Therapeutics Reports Second Quarter 2024 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
17/06/202423h15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KROSKeros Therapeutics Inc
17/06/202422h01GlobeNewswire Inc.Keros Therapeutics Announces Leadership UpdatesNASDAQ:KROSKeros Therapeutics Inc
17/06/202412h00GlobeNewswire Inc.Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
04/06/202414h00GlobeNewswire Inc.Keros Therapeutics to Host a Corporate Update Conference Call and WebcastNASDAQ:KROSKeros Therapeutics Inc
03/06/202414h00GlobeNewswire Inc.Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
28/05/202422h01GlobeNewswire Inc.Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of DirectorsNASDAQ:KROSKeros Therapeutics Inc
14/05/202416h00GlobeNewswire Inc.Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
08/05/202414h00GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
14/03/202413h00GlobeNewswire Inc.Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic SyndromesNASDAQ:KROSKeros Therapeutics Inc
05/03/202414h00GlobeNewswire Inc.Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma ConferenceNASDAQ:KROSKeros Therapeutics Inc
28/02/202422h01GlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
29/01/202414h00GlobeNewswire Inc.Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual CongressNASDAQ:KROSKeros Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KROS

Dernières Valeurs Consultées

NYSE
JPM
JP Morgan Chase
NASDAQ
GOOGL
Alphabet
EU
EN
Bouygues
NASDAQ
NVDA
NVIDIA
EU
ML
Michelin
NYSE
NKE
Nike
EU
ACA
Credit Agricole
EU
LR
Legrand
EU
CS
Axa
COIN
ETHUSD
Ethereum
EU
VK
Vallourec
EU
PX1
CAC 40
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces